Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

10

Sep 2026

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen. Additional proteomic analyses linked treatment to changes in senescence, metabolism, growth-factor signaling, and fibrosis-related pathways, although the study could not determine whether these effects reflected genuine geroprotection rather than disease modification.

Gut microbiome may reveal inflammation and future disease risk better than age

9

Sep 2026

Gut microbiome may reveal inflammation and future disease risk better than age

Gut microbiota composition explained more variation than chronological age in nearly all inflammatory cytokines and most physiological measures examined, with specific microbial profiles linked to markedly different patterns of inflammation across adulthood. People with the Bacteroides 2 enterotype showed an inflammaging-like profile decades earlier than other groups and had a higher risk of subsequent disease, while a high-diversity microbiota profile was associated with lower inflammation and reduced disease incidence.

Yourgene Health launches Insight DPYD assay (IVDR)

9

Sep 2026

Yourgene Health launches Insight DPYD assay (IVDR)

Yourgene Health (part of the Novacyt Group), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the commercial launch of its In Vitro Diagnostic Regulation (IVDR)-certified Yourgene® Insight DPYD assay, expanding the Company's clinical genetics portfolio across regulated European markets.

Blood protein profiling could improve rare disease diagnosis

9

Sep 2026

Blood protein profiling could improve rare disease diagnosis

Researchers from Queen Mary University of London, the Berlin Institute of Health at Charité (BIH) and Genomics England have shown that measuring proteins in the blood can provide important additional clues about the effects of genetic variants, helping to identify diagnoses and potential new disease-causing genes that genome sequencing alone has been unable to resolve.

Why researchers are looking at psilocybin for repeated mild head injuries

9

Sep 2026

Why researchers are looking at psilocybin for repeated mild head injuries

In female rats with repetitive mild head injury, psilocybin reduced acute imaging measures consistent with vasogenic edema and phosphorylated tau while altering vascular reactivity, functional connectivity, neurotrophic proteins, and lipid signaling. The findings provide preclinical evidence of potential therapeutic effects, but behavioral benefits were limited, and whether these biological changes translate into lasting neurological protection or benefits in humans remains unknown.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.